Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer

Technology appraisal guidance
Reference number: TA816
Published: 10 August 2022

History

Expected publication

Register of interests (PDF 142 KB)

Published:

10 August 2022
Equality Impact Assessment (Guidance development) (PDF 157 KB)

Published:

10 August 2022

Final draft guidance

Final draft guidance
Final appraisal document (PDF 329 KB)

Published:

14 July 2022
Committee papers (PDF 877 KB)

Published:

14 July 2022
Public committee slides (PDF 1.38 MB)

Published:

14 July 2022

Draft guidance: 1

Draft guidance: 1
Appraisal consultation document (PDF version) (PDF 309 KB)

Published:

31 March 2022
Committee papers (PDF 6.79 MB)

Published:

31 March 2022
Appraisal consultation document (online commenting)

Invitation to participate

Equality impact assessment (Scoping) (PDF 124 KB)

Published:

17 May 2021
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 287 KB)

Published:

17 May 2021
Final stakeholder list (PDF 186 KB)

Published:

17 May 2021
Final scope (PDF 256 KB)

Published:

17 May 2021